The Host Julie Rovner KFF Health News @jrovner @julierovner.bsky.social Read Julie’s stories. Julie Rovner is chief Washington correspondent and host of KFF Health News’ weekly health policy news podcast, “What the Health?” A noted expert on health policy issues, Julie is the author of the critically praised reference book “Health Care Politics and Policy A…
This chart collection explores how health spending is expected to grow in coming years, with a look at growth in prescription drug spending, out-of-pocket spending, and related trends.
Ballad Health, an Appalachian company with the nation’s largest state-sanctioned hospital monopoly, may soon be required to improve its quality of care or face the possibility of being broken up. Government documents obtained by KFF Health News reveal that Tennessee officials, in closed-door negotiations, are attempting to hold the monopoly more accountable after years of…
An estimated 750,000 to 2 million people would lose health insurance with proposed rule, with the potential to further burden EDs
Healthcare AI is developing at a rapid rate, and the industry’s attitude on how to best regulate and deploy this technology is evolving every day, according to leaders attending this year’s ViVE conference. The post ‘The Hardest Thing Is Separating the Wheat from the Chaff’: 5 Leaders on the State of Healthcare AI appeared first…
Aldeyra said the FDA did not ask for another clinical trial for reproxalap in dry eye disease, but the drug’s mixed record in clinical testing warrants exploration about the reasons for failure, which could identify the appropriate patients for the eye drop. AbbVie holds an option to collaborate on commercialization of reproxalap. The post ‘Lack…
With Sunrise’s women’s health program, the company can support women battling sleep issues due to conditions like pregnancy, polycystic ovary syndrome, perimenopause, menopause and premenstrual syndrome. The post Sunrise Introduces Sleep Offering Tailored to Women appeared first on MedCity News.
Insilico Medicine’s idiopathic pulmonary fibrosis drug led to dose-dependent improvement in lung function in a mid-stage study. Meanwhile, Pliant Therapeutics and PureTech Health are also making Phase 2 progress while Boehringer Ingelheim is planning regulatory submission supported by its IPF drug’s Phase 3 data. The post AI-Designed Insilico Drug Flashes Signs of Efficacy in Lung…
FDA accepts 1st In Silico Drug Development Tool.Why GLP-1’s got more affordable.BALANCE after CMS GLP-1 decision.How to socialize scientific ideas in the age of AI.Mapping the Ebola outbreak.1985-2023: MIT’s faculty grew 9%…Administrative staff grew 189%
Sequoia Project work group co-chairs discuss the state of granular data-sharing consent and some possible approaches to further progress